Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NL 201 - Neurogene Inc

Next Previous
Drug Profile

NL 201 - Neurogene Inc

Alternative Names: NEO-2/15; NL-201 - Neurogene Inc

Latest Information Update: 26 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Washington
  • Developer Merck Sharp & Dohme; Neurogene Inc
  • Class Antineoplastics; Immunotherapies; Proteins
  • Mechanism of Action Interleukin 15 receptor agonists; Interleukin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 19 Dec 2023 Neurogene Inc has merged with Neoleukin Therapeutics to form Neurogene Inc
  • 14 Apr 2023 Pharmacodynamics data from a preclinical studies in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 12 Nov 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top